Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrienX010 vs Dacarbazine in Advanced Melanoma
NCT04200040Phase 2Unknown
- Sponsor
- OrienGene Biotechnology
- Start
- Aug 2017
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of orienx010 in Malignant Melanoma (MM), sponsored by OrienGene Biotechnology. Status: unknown.
02
Drugs
orienx010
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04200040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200040.